Compiled By: Malami Haruna Dogon daji
02 NOVEMBER, 2026
A Landmark Step for Global Health Equity
The historic regulatory decision—granted to Indian manufacturer Dr. Reddy’s Laboratories under the President’s Emergency Plan for AIDS Relief (PEPFAR) framework—brings an accessible version of the highly effective pre-exposure prophylaxis (PrEP) closer to communities across 120 low- and middle-income countries. Originally developed by U.S. pharmaceutical firm Gilead Sciences, the originator drug demonstrated over 99.9 percent efficacy in extensive clinical trials.
While the brand-name formulation commands a high cost in Western markets, these upcoming generics are targeted to roll out affordably. Initial supplies are expected to reach high-incidence regions before the close of the year, paving the way for broader national rollouts across sub-Saharan Africa.
Bridging the Gap from Innovation to Access
Public health advocates have long argued that even the most advanced medical innovations fail if they remain financially out of reach for developing nations. Daily oral PrEP pills, introduced over a decade ago, require rigorous daily adherence, a hurdle that long-acting biannual injections effectively bypass.
International health stakeholders, including Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI, have coordinated closely with global partners to fast-track country-level introductions.
“Unitaid’s early risk-taking is helping shorten the time between a scientific breakthrough and real access in countries. Getting a generic approved just 16 months after the originator approval for prevention, rather than a decade later, shows what’s possible when we prioritize access from the start.”
— Dr. Philippe Duneton, Executive Director, Unitaid
Implications for Public Health Architecture
The rapid progression from brand-name authorization to generic production establishes a vital precedent for future pandemic responses and infectious disease control. By lowering cost barriers, health ministries across developing regions can integrate long-acting injectables into national HIV mitigation strategies with greater speed and scale.
Medical experts emphasize that robust domestic distribution channels, community engagement, and targeted public sensitization will be essential to ensure these life-saving therapeutics reach vulnerable populations efficiently.
The Social Call-to-Action (CTA)
As affordable long-acting HIV prevention options approach widespread rollout, how can public health institutions in Nigeria and across the continent best ensure equitable distribution to remote communities? Share your thoughts on NTA’s social platforms at NTA Network
